{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T11:27:26Z","timestamp":1744630046633,"version":"3.37.3"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T00:00:00Z","timestamp":1651449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"U-CARE Uppsala University Psychosocial Care Programme: U-CARE","award":["DNR 2009-1093"],"award-info":[{"award-number":["DNR 2009-1093"]}]},{"DOI":"10.13039\/100018870","name":"Swedish Heart and Lung Association","doi-asserted-by":"crossref","award":["DNR 2018:32 & 2019:7"],"award-info":[{"award-number":["DNR 2018:32 & 2019:7"]}],"id":[{"id":"10.13039\/100018870","id-type":"DOI","asserted-by":"crossref"}]},{"name":"S\u00f6derstr\u00f6m K\u00f6nig Foundation","award":["941192"],"award-info":[{"award-number":["941192"]}]},{"DOI":"10.13039\/501100018713","name":"Center for Innovative Medicine","doi-asserted-by":"crossref","award":["96328"],"award-info":[{"award-number":["96328"]}],"id":[{"id":"10.13039\/501100018713","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Region Stockholm","award":["2017-4577"],"award-info":[{"award-number":["2017-4577"]}]},{"DOI":"10.13039\/501100003793","name":"Swedish Heart-Lung Foundation","doi-asserted-by":"crossref","award":["DNR 2018-0187"],"award-info":[{"award-number":["DNR 2018-0187"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>\u03b2-blockers are routinely administered to patients following myocardial infarction (MI), yet their potential effect on health-related quality of life (HRQoL) is not entirely understood. We investigated the relationship between two different doses of \u03b2-blockers with HRQoL following MI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>This nationwide observational study used Swedish national registries to collate sociodemographic, clinical, medication, and HRQoL {the latter operationalized using EuroQol [European Quality of Life Five Dimensions Questionnaire (EQ-5D)]}. Estimates at 6\u201310 weeks and 12\u201314 months post-MI follow-up from pooled linear and logistic models were calculated after multiple imputation. We identified 35\u2009612 patients with first-time MI, discharged with \u03b2-blockers, and enrolled in cardiac rehabilitation between 2006 and 2015. Upon discharge, patients were either dispensed &amp;lt;50% [24\u2009082 (67.6%)] or \u226550% [11\u2009530 (32.4%)] of the target dosage, as defined in previous trials. After adjusting for pre-defined covariates, neither the EQ-5D Index nor the Emotional Distress items were statistically different between groups. The EQ-VAS score was significantly lower in patients treated with \u226550% target \u03b2-blocker dose than those treated with &amp;lt;50% of the target dose [\u22120.87 [\u22121.23, \u22120.46], P\u2009&amp;lt;\u2009.001]. Results were similar at the 12-month follow-up and across sub-groups separated by sex and age.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>No difference in HRQoL was found among patients taking &amp;lt;50% vs. \u226550% of the target \u03b2-blocker dose, except for the EQ-VAS in which higher scores were reported in those taking a lower dose. The clinical meaningfulness of this statistical significance is likely low.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjacc\/zuac050","type":"journal-article","created":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T19:10:02Z","timestamp":1650309002000},"page":"491-500","source":"Crossref","is-referenced-by-count":4,"title":["Association between \u03b2-blocker dose and quality of life after myocardial infarction: a real-world Swedish register-linked study"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3680-6351","authenticated-orcid":false,"given":"Sophia","family":"Humphries","sequence":"first","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, Uppsala University , Uppsala , Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1473-4916","authenticated-orcid":false,"given":"John","family":"Wallert","sequence":"additional","affiliation":[{"name":"Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet , Stockholm , Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6739-1558","authenticated-orcid":false,"given":"Katarina","family":"Mars","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, Division of Cardiology, Karolinska Institutet , S\u00f6dersjukhuset, Stockholm , Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9402-7404","authenticated-orcid":false,"given":"Claes","family":"Held","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Cardiology, Uppsala University , Uppsala , Sweden"},{"name":"Uppsala Clinical Research Center, Uppsala University , Uppsala , Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8907-895X","authenticated-orcid":false,"given":"Robin","family":"Hofmann","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, Division of Cardiology, Karolinska Institutet , S\u00f6dersjukhuset, Stockholm , Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1591-7407","authenticated-orcid":false,"given":"Erik M G","family":"Olsson","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, Uppsala University , Uppsala , Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,5,2]]},"reference":[{"key":"2022062217485965600_zuac050-B1","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(05)67661-1","article-title":"Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"2022062217485965600_zuac050-B2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/medicina57020155","article-title":"Neuropsychiatric consequences of lipophilic beta-blockers","volume":"57","author":"Cojocariu","year":"2021","journal-title":"Medicina"},{"key":"2022062217485965600_zuac050-B3","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1001\/archinte.1990.00390220044009","article-title":"Increased prescribing of antidepressants subsequent to beta-blocker therapy","volume":"150","author":"Thiessen","year":"1990","journal-title":"Arch Int Med"},{"key":"2022062217485965600_zuac050-B4","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0002-9343(00)00304-1","article-title":"The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension","volume":"108","author":"P\u00e9rez-Stable","year":"2000","journal-title":"Am J Med"},{"key":"2022062217485965600_zuac050-B5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ahj.2015.11.018","article-title":"Initiation of \u03b2-blocker therapy and depression after acute myocardial infarction","volume":"174","author":"Ranchord","year":"2016","journal-title":"Am Heart J"},{"key":"2022062217485965600_zuac050-B6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cardfail.2004.03.007","article-title":"Depression in patients with heart failure","volume":"11","author":"Westlake","year":"2005","journal-title":"J Card Fail"},{"key":"2022062217485965600_zuac050-B7","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1016\/j.ijcard.2013.05.068","article-title":"Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information","volume":"168","author":"Barron","year":"2013","journal-title":"Int J Cardiol"},{"key":"2022062217485965600_zuac050-B8","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/2047487315569401","article-title":"EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries","volume":"23","author":"Kotseva","year":"2016","journal-title":"Eur J Prev Cardiol"},{"article-title":"Association between b -blocker dose and cardiovascular outcomes after myocardial infarction\u202f: insights from the SWEDEHEART registry","year":"2020","author":"Mars","key":"2022062217485965600_zuac050-B9"},{"key":"2022062217485965600_zuac050-B10","doi-asserted-by":"crossref","first-page":"e005103","DOI":"10.1161\/CIRCOUTCOMES.118.005103","article-title":"Comparative effectiveness of \u03b2-blocker use beyond 3 years after myocardial infarction and long-term outcomes among elderly patients","volume":"12","author":"Shavadia","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2022062217485965600_zuac050-B11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"key":"2022062217485965600_zuac050-B12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7525-8-13","article-title":"A review of health utilities using the EQ-5D in studies of cardiovascular disease","volume":"8","author":"Dyer","year":"2010","journal-title":"Health Qual Life Outcomes"},{"key":"2022062217485965600_zuac050-B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1002540","article-title":"Comorbidity health pathways in heart failure patients: a sequences-of-regressions analysis using cross-sectional data from 10,575 patients in the Swedish Heart Failure Registry","volume":"15","author":"Lawson","year":"2018","journal-title":"PLoS Med"},{"key":"2022062217485965600_zuac050-B14","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1177\/2047487319841475","article-title":"Persistent emotional distress after a first-time myocardial infarction and its association to late cardiovascular and non-cardiovascular mortality","volume":"26","author":"Liss\u00e5ker","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"2022062217485965600_zuac050-B15","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.638829","article-title":"Routine oxygen therapy does not improve health-related quality of life in patients with acute myocardial infarction\u2014insights from the randomized DETO2X-AMI trial","volume":"8","author":"Hofmann","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2022062217485965600_zuac050-B16","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/ehjqcco\/qcab039","article-title":"The SWEDEHEART secondary prevention and cardiac rehabilitation registry (SWEDEHEART CR registry)","volume":"7","author":"B\u00e4ck","year":"2021","journal-title":"Eur Hear J Qual Care Clin Outcomes"},{"key":"2022062217485965600_zuac050-B17","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"year":"2016","key":"2022062217485965600_zuac050-B18"},{"key":"2022062217485965600_zuac050-B19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-94-007-7596-1_3","volume-title":"Self-Reported Population Health: An International Perspective Based on EQ-5D","author":"Janssen","year":"2014"},{"key":"2022062217485965600_zuac050-B20","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0140-6736(81)91101-6","article-title":"Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial","volume":"318","author":"Hjalmarson","year":"1981","journal-title":"Lancet"},{"key":"2022062217485965600_zuac050-B21","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJM198104023041401","article-title":"Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction","volume":"304","author":"Norwegian Multicenter Study Group","year":"1981","journal-title":"N Engl J Med"},{"key":"2022062217485965600_zuac050-B22","first-page":"1707","article-title":"A randomized trial of propranolol in patients with acute myocardial infarction: I. Mortality results","volume-title":"J Am Med Assoc","author":"National Heart, Lung, and Blood Institute","year":"1982"},{"key":"2022062217485965600_zuac050-B23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/oxfordjournals.eurheartj.a061845","article-title":"Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial","volume":"6","author":"The MIAMI Trial Research Group","year":"1985","journal-title":"Eur Heart J"},{"key":"2022062217485965600_zuac050-B24","first-page":"1","article-title":"Groothuis-Oudshoorn K. mice: multivariate imputation by chained equations in R","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Stat Softw"},{"key":"2022062217485965600_zuac050-B25","doi-asserted-by":"crossref","DOI":"10.1002\/9780470316696","volume-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"1987"},{"article-title":"R: A Language and Environment for Statistical Computing","year":"2021","author":"R Core Team","key":"2022062217485965600_zuac050-B26"},{"key":"2022062217485965600_zuac050-B27","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2020.23138","article-title":"Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial","volume":"324","author":"Kotecha","year":"2020","journal-title":"J Am Med Assoc"},{"key":"2022062217485965600_zuac050-B28","first-page":"1","article-title":"ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"2020","author":"Collet","year":"2020","journal-title":"Eur Heart J"},{"key":"2022062217485965600_zuac050-B29","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4187\/respcare.03272","article-title":"Estimation of minimal clinically important difference in EQ-5D visual analog scale score after pulmonary rehabilitation in subjects with COPD","volume":"60","author":"Zanini","year":"2015","journal-title":"Respir Care"},{"key":"2022062217485965600_zuac050-B30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/thoraxjnl-2020-214944","article-title":"Minimum important difference of the EQ-5D-5L and EQ-VAS in fibrotic interstitial lung disease","volume":"76","author":"Tsai","year":"2021","journal-title":"Thorax"},{"key":"2022062217485965600_zuac050-B31","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ahj.2016.10.012","article-title":"\u03b2-blocker dosage and outcomes after acute coronary syndrome","volume":"184","author":"Allen","year":"2017","journal-title":"Am Heart J"},{"key":"2022062217485965600_zuac050-B32","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jacc.2015.07.047","article-title":"Effect of beta-blocker dose on survival after acute myocardial infarction","volume":"66","author":"Goldberger","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2022062217485965600_zuac050-B33","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1253\/circj.CJ-18-0662","article-title":"Prognostic impact of \u03b2-blocker dose after acute myocardial infarction","volume":"83","author":"Hwang","year":"2019","journal-title":"Circ J"},{"key":"2022062217485965600_zuac050-B34","doi-asserted-by":"crossref","first-page":"708200","DOI":"10.3389\/fcvm.2021.708200","article-title":"Sexual dysfunction and the impact of beta-blockers in young males with coronary artery disease","volume":"8","author":"Dai","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2022062217485965600_zuac050-B35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3810\/pgm.2010.11.2223","article-title":"Erectile dysfunction may improve by blood pressure control in patients with high-risk hypertension","volume":"122","author":"Cordero","year":"2010","journal-title":"Postgrad Med"},{"key":"2022062217485965600_zuac050-B36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2020.07.009","article-title":"Erectile dysfunction and adherence to antihypertensive therapy: focus on \u03b2-blockers","volume":"81","author":"Manolis","year":"2020","journal-title":"European Journal of Internal Medicine"},{"key":"2022062217485965600_zuac050-B37","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/S0895-7061(98)00139-3","article-title":"Sexual function in hypertensive males treated with lisinopril or atenolol a cross-over study","volume":"11","author":"Fogari","year":"1998","journal-title":"Am J Hypertens"},{"key":"2022062217485965600_zuac050-B38","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1525-1497.1998.00050.x","article-title":"Health-related quality of life in men with erectile dysfunction","volume":"13","author":"Litwin","year":"1998","journal-title":"J Gen Intern Med"},{"key":"2022062217485965600_zuac050-B39","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1097\/HJH.0b013e32830dd0c6","article-title":"Sexual dysfunction: the \u2018prima ballerina\u2019 of hypertension-related quality-of-life complications","volume":"26","author":"Manolis","year":"2008","journal-title":"J Hypertens"},{"key":"2022062217485965600_zuac050-B40","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S0735-1097(02)02379-3","article-title":"Outpatient adherence to beta-blocker therapy after acute myocardial infarction","volume":"40","author":"Butler","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2022062217485965600_zuac050-B41","doi-asserted-by":"crossref","first-page":"454.e1","DOI":"10.1016\/j.ahj.2006.02.030","article-title":"National evaluation of adherence to \u03b2-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance","volume":"152","author":"Kramer","year":"2006","journal-title":"Am Heart J"},{"key":"2022062217485965600_zuac050-B42","first-page":"pvab060","article-title":"Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT)","author":"Rossello","year":"2021","journal-title":"Eur Hear J Cardiovasc Pharmacother"}],"container-title":["European Heart Journal. Acute Cardiovascular Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjacc\/article-pdf\/11\/6\/491\/44171399\/zuac050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjacc\/article-pdf\/11\/6\/491\/44171399\/zuac050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T17:50:25Z","timestamp":1655920225000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjacc\/article\/11\/6\/491\/6576486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,2]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,5,2]]},"published-print":{"date-parts":[[2022,6,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjacc\/zuac050","relation":{},"ISSN":["2048-8726","2048-8734"],"issn-type":[{"type":"print","value":"2048-8726"},{"type":"electronic","value":"2048-8734"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2022,5,2]]}}}